IDP Pharma will present at the Annual Meeting of the American Association for Cancer Research (June 22-24) its first in class c-Myc inhibitor program, expected to enter clinical trails in 2021.

Quando sono tornato a casa, i medici hanno scoperto che il mio cuore era ingrossato e che soffrivo di tubercolosi, un’infezione mortale e fatale che poteva essere diagnosticata solo dopo la leggi qui morte. La mia prima esperienza di trapianto d’organo è seguita dopo un’operazione sulla mia gamba. L’organo è stato trapiantato nella coscia destra di un giovane che non vedevo da quasi trent’anni.

The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research, clinical studies and highlights the work of the best minds in research and medicine from institutions all over the world.

IDP Pharma has closed today a 2M€ private funding round. The company will allocate the funding to start clinical activities of IDP-121 (solid and haem tumors), to complete the formulation of IDP-233 (neuroendocrine tumors) and to exploit its technological platform (IDP Platform).

The company has received further support from RETOS public program (1M€) to advance innovative research in collaboration with CIMA and Univertisy of Navarra.